Literature DB >> 10576911

Increased circulating levels of lipopolysaccharide binding protein in children with Escherichia coli O157:H7 hemorrhagic colitis and hemolytic uremic syndrome.

F Proulx, E Seidman, M M Mariscalco, K Lee, S Caroll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10576911      PMCID： PMC95773          DOI： 10.1128/CDLI.6.5.773-773.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  5 in total

1.  CD14 and immune response to lipopolysaccharide.

Authors:  C R Maliszewski
Journal:  Science       Date:  1991-05-31       Impact factor: 47.728

2.  The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection.

Authors:  D Karpman; H Connell; M Svensson; F Scheutz; P Alm; C Svanborg
Journal:  J Infect Dis       Date:  1997-03       Impact factor: 5.226

3.  Immunoreactivity and bioactivity of lipopolysaccharide-binding protein in normal and heat-inactivated sera.

Authors:  K Mészáros; S Aberle; M White; J B Parent
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

4.  Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes.

Authors:  F Koster; J Levin; L Walker; K S Tung; R H Gilman; M M Rahaman; M A Majid; S Islam; R C Williams
Journal:  N Engl J Med       Date:  1978-04-27       Impact factor: 91.245

5.  Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome.

Authors:  F Proulx; J P Turgeon; C Litalien; M M Mariscalco; P Robitaille; E Seidman
Journal:  Pediatr Infect Dis J       Date:  1998-10       Impact factor: 2.129
  5 in total
  9 in total

1.  Increased levels of macrophage migration inhibitory factor in sera of patients with Escherichia coli O157:H7-induced enterocolitis.

Authors:  Tatsuya Ohkawara; Hiroshi Takeda; Masahiro Asaka; Yuka Mizue; Jun Nishihira
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

2.  Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome.

Authors:  Patricia G Vallés; Silvia Melechuck; Adriana González; Walter Manucha; Victoria Bocanegra; Roberto Vallés
Journal:  Pediatr Nephrol       Date:  2011-10-05       Impact factor: 3.714

3.  Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy.

Authors:  C Elsing; S Ernst; N Kayali; W Stremmel; S Harenberg
Journal:  Infection       Date:  2011-04-27       Impact factor: 3.553

4.  Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Majlis Svensson; Matthias Mörgelin; Catharina Svanborg; Phillip I Tarr; Jody C Mooney; Sandra L Watkins; Roger Johnson; Diana Karpman
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

5.  Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein.

Authors:  Maja Pavcnik-Arnol; Sergej Hojker; Metka Derganc
Journal:  Intensive Care Med       Date:  2004-05-04       Impact factor: 17.440

6.  Lipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2.

Authors:  Thomas P Griener; Jonathan G Strecker; Romney M Humphries; George L Mulvey; Carmen Fuentealba; Robert E W Hancock; Glen D Armstrong
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

7.  Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease.

Authors:  Sophie Dennhardt; Wiebke Pirschel; Bianka Wissuwa; Christoph Daniel; Florian Gunzer; Sandro Lindig; Anna Medyukhina; Michael Kiehntopf; Wolfram W Rudolph; Peter F Zipfel; Matthias Gunzer; Marc Thilo Figge; Kerstin Amann; Sina M Coldewey
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

8.  Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients.

Authors:  Miroslav Prucha; Ivan Herold; Roman Zazula; Ladislava Dubska; Miroslav Dostal; Thomas Hildebrand; Josef Hyanek
Journal:  Crit Care       Date:  2003-10-01       Impact factor: 9.097

Review 9.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review.

Authors:  Adrien Joseph; Aurélie Cointe; Patricia Mariani Kurkdjian; Cédric Rafat; Alexandre Hertig
Journal:  Toxins (Basel)       Date:  2020-01-21       Impact factor: 4.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.